Dyskeratosis Congenita

Hematology/Oncology Clinics of North America

Volumn 23, Issue 2, 2009, Pages 215-231

  Savage, Sharon A ^a   Alter, Blanche P ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bone marrow failure; DKC1; Dyskeratosis congenita; Telomere; TERC; TERT; TINF2

Indexed keywords

DYSKERIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOSUPPRESSIVE AGENT; OXYMETHOLONE; TELOMERASE;

BONE CANCER; BONE MARROW DEPRESSION; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DYSKERATOSIS CONGENITA; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; LUNG FIBROSIS; MORBIDITY; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TELOMERE;

BONE MARROW DISEASES; DYSKERATOSIS CONGENITA; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSION; TELOMERE;

EID: 62649107214     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.hoc.2009.01.003     Document Type: Review

References (69)

1. Drachtman R.A., and Alter B.P. Dyskeratosis congenita: clinical and genetic heterogeneity. Report of a new case and review of the literature. Am J Pediatr Hematol Oncol 14 4 (1992) 297-304
2. Walne A.J., and Dokal I. Dyskeratosis congenita: a historical perspective. Mech Ageing Dev 129 1-2 (2008) 48-59
3. Alter B.P., Baerlocher G.M., Savage S.A., et al. Very short telomere length by flow fluorescence in situ hybridization identifies patients with dyskeratosis congenita. Blood 110 5 (2007) 1439-1447
4. Mitchell J.R., Wood E., and Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature 402 6761 (1999) 551-555
5. Savage S.A., and Alter B.P. The role of telomere biology in bone marrow failure and other disorders. Mech Ageing Dev 129 1-2 (2008) 35-47
6. Zinsser F. Atrophia Cutis Reticularis cum Pigmentations, Dystrophia Unguium et Leukoplakis oris (Poikioodermia atrophicans vascularis Jacobi). Ikonographia Dermatologica 5 (1910) 219-223 [in German]
7. Engman M.F.S. A unique case of reticular pigmentation of the skin with atrophy. Arch Belg Dermatol Syphiligr 13 (1926) 685-687
8. Cole H.N., Rauschkolb J., and Toomey J. Dyskeratosis congenita with pigmentation, dystrophia unguis and leukokeratosis oris. Archives of Dermatology and Syphilology 21 (1930) 71-95
9. Dokal I. Dyskeratosis congenita in all its forms. Br J Haematol 110 4 (2000) 768-779
10. Young N.S., and Alter B.P. Aplastic anemia acquired and inherited (1994), W.B. Saunders Company, Philadelphia
11. Vulliamy T.J., Marrone A., Knight S.W., et al. Mutations in dyskeratosis congenita: their impact on telomere length and the diversity of clinical presentation. Blood 107 7 (2006) 2680-2685
12. Savage S.A., Giri N., Baerlocher G.M., et al. TINF2, a component of the shelterin telomere protection complex, is mutated in dyskeratosis congenita. Am J Hum Genet 82 2 (2008) 501-509
13. Hoyeraal H.M., Lamvik J., and Moe P.J. Congenital hypoplastic thrombocytopenia and cerebral malformations in two brothers. Acta Paediatr Scand 59 2 (1970) 185-191
14. Hreidarsson S., Kristjansson K., Johannesson G., et al. A syndrome of progressive pancytopenia with microcephaly, cerebellar hypoplasia and growth failure. Acta Paediatr Scand 77 5 (1988) 773-775
15. Aalfs C.M., van den B.H., Barth P.G., and Hennekam R.C. The Hoyeraal-Hreidarsson syndrome: the fourth case of a separate entity with prenatal growth retardation, progressive pancytopenia and cerebellar hypoplasia. Eur J Pediatr 154 4 (1995) 304-308
16. Sznajer Y., Baumann C., David A., et al. Further delineation of the congenital form of X-linked dyskeratosis congenita (Hoyeraal-Hreidarsson syndrome). Eur J Pediatr 162 12 (2003) 863-867
17. Walne A.J., Vulliamy T., Beswick R., et al. TINF2 mutations result in very short telomeres: analysis of a large cohort of patients with dyskeratosis congenita and related bone marrow failure syndromes. Blood 112 9 (2008) 3594-3600
18. Marrone A., Walne A., Tamary H., et al. Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome. Blood 110 13 (2007) 4198-4205
19. Revesz T., Fletcher S., Gazali L.I., et al. Bilateral retinopathy, aplastic anaemia, and central nervous system abnormalities: a new syndrome?. J Med Genet 29 9 (1992) 673-675
20. Kajtar P., and Mehes K. Bilateral coats retinopathy associated with aplastic anaemia and mild dyskeratotic signs. Am J Med Genet 49 4 (1994) 374-377
21. Heiss N.S., Knight S.W., Vulliamy T.J., et al. X-linked dyskeratosis congenita is caused by mutations in a highly conserved gene with putative nucleolar functions. Nat Genet 19 1 (1998) 32-38
22. Vulliamy T., Beswick R., Kirwan M., et al. Mutations in the telomerase component NHP2 cause the premature ageing syndrome dyskeratosis congenita. Proc Natl Acad Sci U S A 105 23 (2008) 8073-8078
23. Walne A.J., Vulliamy T., Marrone A., et al. Genetic heterogeneity in autosomal recessive dyskeratosis congenita with one subtype due to mutations in the telomerase-associated protein NOP10. Hum Mol Genet 16 13 (2007) 1619-1629
24. Aubert G., and Lansdorp P.M. Telomeres and aging. Physiol Rev 88 2 (2008) 557-579
25. Wong J.M., and Collins K. Telomerase RNA level limits telomere maintenance in X-linked dyskeratosis congenita. Genes Dev 20 20 (2006) 2848-2858
26. Vulliamy T., Marrone A., Szydlo R., et al. Disease anticipation is associated with progressive telomere shortening in families with dyskeratosis congenita due to mutations in TERC. Nat Genet 36 5 (2004) 447-449
27. Yamaguchi H., Baerlocher G.M., Lansdorp P.M., et al. Mutations of the human telomerase RNA gene (TERC) in aplastic anemia and myelodysplastic syndrome. Blood 102 3 (2003) 916-918
28. Armanios M.Y., Chen J.J., Cogan J.D., et al. Telomerase mutations in families with idiopathic pulmonary fibrosis. N Engl J Med 356 13 (2007) 1317-1326
29. Yamaguchi H., Calado R.T., Ly H., et al. Mutations in TERT, the gene for telomerase reverse transcriptase, in aplastic anemia. N Engl J Med 352 14 (2005) 1413-1424
30. Savage S.A., Stewart B.J., Weksler B.B., et al. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol Dis 37 2 (2006) 134-136
31. Vulliamy T.J., Walne A., Baskaradas A., et al. Mutations in the reverse transcriptase component of telomerase (TERT) in patients with bone marrow failure. Blood Cells Mol Dis 34 3 (2005) 257-263
32. Tsakiri K.D., Cronkhite J.T., Kuan P.J., et al. Adult-onset pulmonary fibrosis caused by mutations in telomerase. Proc Natl Acad Sci U S A 104 18 (2007) 7552-7557
33. Armanios M., Chen J.L., Chang Y.P., et al. Haploinsufficiency of telomerase reverse transcriptase leads to anticipation in autosomal dominant dyskeratosis congenita. Proc Natl Acad Sci U S A 102 44 (2005) 15960-15964
34. Baird D.M. New developments in telomere length analysis. Exp Gerontol 40 5 (2005) 363-368
35. Lin K.W., and Yan J. The telomere length dynamic and methods of its assessment. J Cell Mol Med 9 4 (2005) 977-989
36. Baerlocher G.M., and Lansdorp P.M. Telomere length measurements in leukocyte subsets by automated multicolor flow-FISH. Cytometry A 55 1 (2003) 1-6
37. Ball S.E., Gibson F.M., Rizzo S., et al. Progressive telomere shortening in aplastic anemia. Blood 91 10 (1998) 3582-3592
38. Du H.Y., Pumbo E., Ivanovich J., et al. TERC and TERT gene mutations in patients with bone marrow failure and the significance of telomere length measurements. Blood (2008)
39. Rufer N., Dragowska W., Thornbury G., et al. Telomere length dynamics in human lymphocyte subpopulations measured by flow cytometry. Nat Biotechnol 16 8 (1998) 743-747
40. Baerlocher G.M., and Lansdorp P.M. Telomere length measurements using fluorescence in situ hybridization and flow cytometry. Methods Cell Biol 75 (2004) 719-750
41. Frenck Jr. R.W., Blackburn E.H., and Shannon K.M. The rate of telomere sequence loss in human leukocytes varies with age. Proc Natl Acad Sci U S A 95 10 (1998) 5607-5610
42. Rufer N., Brummendorf T.H., Kolvraa S., et al. Telomere fluorescence measurements in granulocytes and T lymphocyte subsets point to a high turnover of hematopoietic stem cells and memory T cells in early childhood. J Exp Med 190 2 (1999) 157-167
43. Slagboom P.E., Droog S., and Boomsma D.I. Genetic determination of telomere size in humans: a twin study of three age groups. Am J Hum Genet 55 5 (1994) 876-882
44. Zeichner S.L., Palumbo P., Feng Y., et al. Rapid telomere shortening in children. Blood 93 9 (1999) 2824-2830
45. Al Rahawan M.M., Giri N., and Alter B.P. Intensive immunosuppression therapy for aplastic anemia associated with dyskeratosis congenita. Int J Hematol 83 3 (2006) 275-276
46. Yabe M., Yabe H., Hattori K., et al. Fatal interstitial pulmonary disease in a patient with dyskeratosis congenita after allogeneic bone marrow transplantation. Bone Marrow Transplant 19 4 (1997) 389-392
47. Ostronoff F., Ostronoff M., Calixto R., et al. Fludarabine, cyclophosphamide, and antithymocyte globulin for a patient with dyskeratosis congenita and severe bone marrow failure. Biol Blood Marrow Transplant 13 3 (2007) 366-368
48. Brazzola P., Duval M., Fournet J.C., et al. Fatal diffuse capillaritis after hematopoietic stem-cell transplantation for dyskeratosis congenita despite low-intensity conditioning regimen. Bone Marrow Transplant 36 12 (2005) 1103-1105
49. de la Fuente J., and Dokal I. Dyskeratosis congenita: advances in the understanding of the telomerase defect and the role of stem cell transplantation. Pediatr Transplant 11 6 (2007) 584-594
50. Dror Y., Freedman M.H., Leaker M., et al. Low-intensity hematopoietic stem-cell transplantation across human leucocyte antigen barriers in dyskeratosis congenita. Bone Marrow Transplant 31 10 (2003) 847-850
51. Denny C.C., Wilfond B.S., Peters J.A., et al. All in the family: disclosure of "unwanted" information to an adolescent to benefit a relative. Am J Med Genet A 146A 21 (2008) 2719-2724
52. Marrone A., Sokhal P., Walne A., et al. Functional characterization of novel telomerase RNA (TERC) mutations in patients with diverse clinical and pathological presentations. Haematologica 92 8 (2007) 1013-1020
53. National Cancer institute. Inherited bone marrow failure syndromes. Available at:. http://marrowfailure.cancer.gov Accessed March 4, 2009
54. Rosenberg P, Giri N, Savage SA, et al. Cancer epidemiology in the National Cancer Institute inherited bone marrow failure syndromes cohort: first report. ASH Annual Meeting, San Francisco, CA, December 6-9, 2008.
55. Savage SA, Dokal I, Armanios M, et al. Dyskeratosis congenita: the first NIH clinical research workshop. Pediatr Blood Cancer, manuscript under review.
56. Vulliamy T., and Dokal I. Dyskeratosis congenita. Semin Hematol 43 3 (2006) 157-166
57. Alter B.P. Diagnosis, genetics, and management of inherited bone marrow failure syndromes. Hematology Am Soc Hematol Educ Program 2007 (2007) 29-39
58. Alder J.K., Chen J.J., Lancaster L., et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A 105 35 (2008) 13051-13056
59. Tsangaris E., Adams S.L., Yoon G., et al. Ataxia and pancytopenia caused by a mutation in TINF2. Hum Genet 124 5 (2008) 507-513
60. Mahiques L., Febrer I., Vilata J.J., et al. A case of dyskeratosis congenita associated with schizophrenia and two malignancies. J Eur Acad Dermatol Venereol 20 9 (2006) 1159-1161
61. Milgrom H., Sroll Jr. H.L., and Crissey J.T. Dyskeratosis congenita. A case with new features. Arch Dermatol 89 (1964) 345-349
62. Mason III JO, Yunker JJ, Nixon PA, et al. Proliferative retinopathy as a complication of dyskeratosis congenita. Retinal Cases and Brief Reports. in press.
63. In: Owen J., Frohnmayer L., and Eiler M.E. (Eds). Fanconi anemia: standards for clinical care (2003), Fanconi Anemia Research Fund, Inc, Eugene (OR) p. 184
64. Velazquez I., and Alter B.P. Androgens and liver tumors: Fanconi 's anemia and non-Fanconi 's conditions. Am J Hematol 77 3 (2004) 257-267
65. Giri N., Pitel P.A., Green D., et al. Splenic peliosis and rupture in patients with dyskeratosis congenita on androgens and granulocyte colony-stimulating factor. Br J Haematol 138 6 (2007) 815-817
66. Alter B.P., Gardner F.H., and Hall R.E. Treatment of dyskeratosis congenita with granulocyte colony-stimulating factor and erythropoietin. Br J Haematol 97 2 (1997) 309-311
67. Berthou C., Devergie A., D'Agay M.F., et al. Late vascular complications after bone marrow transplantation for dyskeratosis congenita. Br J Haematol 79 2 (1991) 335-336
68. Tolar J, Orchard PJ, Miller JS, et al. Dyskeratosis congenita: low regimen-related toxicity following hematopoietic cell transplantation (HCT) using a reduced intensity conditioning regimen. ASH Annual Meeting, Atlanta, GA, December 8-11, 2007.
69. Fogarty P.F., Yamaguchi H., Wiestner A., et al. Late presentation of dyskeratosis congenita as apparently acquired aplastic anaemia due to mutations in telomerase RNA. Lancet 362 9396 (2003) 1628-1630